Halozyme Therapeutics reported $492.97M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 10.4B 300M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 47.6M 19M Sep/2026
DBV Technologies USD 1.6M 955K Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 243M 25M Sep/2026
MannKind USD 101.9M 7.47M Sep/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Pfizer USD 16.6B 1.57B Sep/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
United Therapeutics USD 832.5M 49.2M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024